YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-29
DOI
10.1038/s41598-021-91623-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity
- (2018) Sabine Hoves et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
- (2018) Pooja Dhupkar et al. Cancer Medicine
- Mechanism Based Quality Control (MBQC) of Herbal Products: A Case Study YIV-906 (PHY906)
- (2018) Wing Lam et al. Frontiers in Pharmacology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node
- (2017) Lifang Cheng et al. MOLECULAR THERAPY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies
- (2017) Géraldine Genard et al. Frontiers in Immunology
- Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan
- (2016) W Chen et al. Cell Death & Disease
- Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin
- (2015) H-Y Tan et al. Cell Death & Disease
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
- (2015) Wing Lam et al. BMC Complementary and Alternative Medicine
- PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment
- (2015) Wing Lam et al. Scientific Reports
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Macrophage Regulation of Tumor Responses to Anticancer Therapies
- (2013) Michele De Palma et al. CANCER CELL
- First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
- (2013) Muhammad Wasif Saif et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Natural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cells
- (2012) S. Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Preclinical studies of the Chinese Herbal Medicine formulation PHY906 (KD018) as a potential adjunct to radiation therapy
- (2012) Sara Rockwell et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy
- (2012) Shwu-Huey Liu et al. JOURNAL OF ETHNOPHARMACOLOGY
- Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
- (2011) Ena Wang et al. BMC Medical Genomics
- The development and functions of CD4+ T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope
- (2011) Xue Han et al. Cellular & Molecular Immunology
- A Phase I Study of the Chinese Herbal Medicine PHY906 as a Modulator of Irinotecan-based Chemotherapy in Patients with Advanced Colorectal Cancer
- (2011) Shivaani Kummar et al. Clinical Colorectal Cancer
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS)
- (2010) Wei Zhang et al. JOURNAL OF CHROMATOGRAPHY A
- Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies
- (2010) M. Wasif Saif et al. PHYTOMEDICINE
- The Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced Gastrointestinal Toxicity
- (2010) W. Lam et al. Science Translational Medicine
- A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqi Tang (HQT) and PHY906
- (2010) Robert Tilton et al. Chinese Medicine
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now